Cytokinetics Inc vs United States Natural Gas Fund — how do they compare? Cytokinetics Inc trades at $82.6 (market cap $11.12B), while United States Natural Gas Fund trades at $10.44. The key difference: Cytokinetics Inc is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| CYTK | UNG | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Commodities - Energy |
52-Week High | $87.26 | $16.90 |
52-Week Low | $33.23 | $10.15 |
Enterprise Value | $11.59B | — |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
UNG trades at $10.37, down 2.17% today, with a bearish technical signal from moving averages. The fund tracks natural gas futures, facing headwinds from contango effects and weather-dependent demand. Recent news highlights volatility tied to LNG exports and storage data, with EIA forecasting record 2026 supply and demand (Reuters, 2026-06-09).
Outlook remains cautious due to structural challenges in futures roll costs and price sensitivity to weather. Risks include production swings and geopolitical factors, while opportunities hinge on sustained LNG demand growth. Long-term performance has been hampered by contango, as noted by 24/7 Wall Street (2026-05-28).
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →